Syndax Pharmaceuticals (NASDAQ:SNDX) Chief Executive Officer Michael A. Metzger executed a sale of 17,159 shares of common stock on February 9, 2026, at a price of $21.028 per share. The filing shows the total proceeds from the transaction amounted to $360,819.
The disposition was reported on a Form 4 filed with the Securities and Exchange Commission and, according to the filing, the sale was undertaken to cover tax withholding obligations that arose when restricted stock units vested. After the transaction, Metzger is recorded as directly owning 491,690 shares of Syndax.
SNDX shares have appreciated materially over recent months, gaining nearly 70% over the past six months and trading near a 52-week high of $22.73, per InvestingPro data. The company’s market capitalization currently stands at $1.84 billion.
Independent analyst coverage detailed in InvestingPro materials suggests a wider market view that SNDX may be undervalued, with published price targets spanning from $27 to $56. The company is listed among more than 1,400 U.S. equities covered by comprehensive Pro Research Reports.
Several sell-side firms have recently reiterated bullish stances on Syndax, citing commercial and clinical developments:
- B. Riley maintained a Buy rating with a $33.00 price target, pointing to persistent commercial momentum for therapies Syndax markets in partnership arrangements and noting strong performance data for the Incyte-partnered drug Niktimvo. The firm highlighted weekly sales that rose significantly in early 2026.
- H.C. Wainwright reaffirmed its Buy rating and kept a $40.00 price target following Syndax’s presentations at the ASH 2025 conference, where data showcased Revuforj’s effectiveness in real-world use and sustained trial responses even among patients with more advanced stages of disease.
- TD Cowen reiterated a Buy rating, observing Syndax’s active presence at the American Society of Hematology meeting where the company displayed Revuforj and Niktimvo across presentations and educational sessions.
Among the clinical data highlighted at meetings and in reports, Syndax’s presentation included results for Revuforj that showed a 77% overall response rate in particular acute leukemia cohorts, with a notable portion of responders achieving measurable residual disease negativity.
The Form 4 sale by Metzger did not include any additional comments beyond the tax-withholding explanation. The filing, the market movements and the analyst commentary together present a snapshot of executive stock activity occurring alongside rising market valuation and continued coverage from multiple broker-dealers.